Diuresis, vasodilation, a renal dip and the switch to tablets are traced for one composite heart failure patient by the MN650 Unit 10 case, each drug followed to its last order. Searches like "mn 650 unit 10 assignment example", "mn650 unit 10 sample" and "mn650 unit 10 example" land here.
Five Days From Intravenous to Oral: A Comprehensive Pharmacotherapy Case in Acute Decompensated Heart Failure
[Student Name]
Purdue University Global
MN650: Specialized Pharmacology for the AGACNP Acute Care NP
Unit 10 Assignment
[Instructor Name]
[Date]
Composite patient written as a model document. Doses and conversion factors are bracketed placeholders; nothing here is a prescribing instruction.
Day 1: Admission
Assessment. A composite 71-year-old retired letter carrier with heart failure with reduced ejection fraction, ejection fraction 30 percent, arrives with three days of worsening breathlessness and orthopnea. Weight 96 kg against a dry weight near 88 kg. Blood pressure 168/94, heart rate 102, oxygen saturation 89 percent on room air, crackles to mid-lung fields, jugular venous pressure raised, leg edema to the knees. Creatinine 1.3 mg/dL; potassium 4.2; BNP markedly raised. Home regimen: oral furosemide [40] mg daily, [carvedilol], [sacubitril-valsartan]; he admits to missing furosemide doses and eating salty food at a family gathering.
Change. Nitroglycerin infusion at [10] mcg/min, titrated by [10 to 20] mcg/min every [5 to 10] minutes up to [200] mcg/min, for pulmonary edema with high blood pressure. Intravenous furosemide at [2.5] times the home oral dose, [100] mg a day, divided twice daily. Carvedilol continued at a reduced dose because he is not in shock; sacubitril-valsartan held while nitroglycerin runs and blood pressure is being lowered.
Reason. In the DOSE trial, a high-dose strategy of 2.5 times the oral dose produced greater fluid loss and a trend toward better relief of breathlessness than a low-dose strategy, with only a transient rise in creatinine (Felker et al., 2011). Nitroglycerin lowers filling pressures quickly while diuresis begins.
Monitoring. Blood pressure every [15] minutes during nitroglycerin titration; urine output hourly; weight daily; basic metabolic panel every [12] hours.
Day 2: Setting a Fluid Goal
Assessment. Urine output 3.1 liters in 24 hours; weight 94.2 kg. Breathing easier; oxygen weaned to 2 liters. Blood pressure 132/78. Potassium 3.6, magnesium 1.7.
Change. Net fluid goal of negative [2 to 3] liters a day. Nitroglycerin weaned off. Potassium and magnesium replaced to keep potassium above 4.0 and magnesium above 2.0.
Reason. A defined goal tells the team whether the diuretic dose is working, rather than judging it by feel.
Monitoring. Strict intake and output; electrolytes twice daily. He was taught to read the scale on the unit each morning before breakfast, since daily weights will be his main tool at home, and his wife was shown the fluid and salt limits on the menu.
Day 3: Creatinine Rises
Assessment. Creatinine 1.7 mg/dL, up from 1.3. Weight 92.4 kg, still 4 kg above dry weight; crackles at the bases and edema to the ankles. Urine output adequate.
Change. Continue diuresis at the same dose.
Reason. A modest rise in creatinine during effective decongestion does not carry the poor prognosis it once seemed to, and stopping diuresis now would leave him congested. In a study of patients with acute heart failure, worsening renal function was associated with worse outcomes mainly when congestion persisted; when it occurred alongside successful decongestion, it was not (Metra et al., 2012). The findings that would change this decision are named in advance: a creatinine above [2.2], potassium above 5.5, falling urine output despite the diuretic, or low blood pressure with signs of poor perfusion.
Monitoring. Creatinine and potassium every 12 hours.
Day 4: Guideline-Directed Therapy
Assessment. Weight 90.1 kg; creatinine 1.6 and falling. Blood pressure 118/72.
Change. Restart sacubitril-valsartan at [a lower composite dose]. Add [spironolactone] and [an SGLT2 inhibitor]. Continue carvedilol.
Reason. The 2022 heart failure guideline recommends four medication classes for heart failure with reduced ejection fraction: an angiotensin receptor-neprilysin inhibitor, an evidence-based beta-blocker, a mineralocorticoid receptor antagonist and an SGLT2 inhibitor (Heidenreich et al., 2022). Starting them in hospital, once he is stable, raises the chance that he leaves on all four.
Monitoring. Potassium and creatinine in [48] hours; blood pressure and symptoms of low pressure.
Day 5: Transfer
Assessment. Weight 88.6 kg, near dry weight; lungs clear; no edema. Creatinine 1.5; potassium 4.4.
Transfer orders:
Intravenous furosemide [100] mg a day, divided twice daily, becomes oral torsemide [40] mg daily. Conversion: oral furosemide has variable bioavailability of roughly 50 percent, so a direct milligram swap from intravenous to oral furosemide would underdose; torsemide is absorbed more reliably, with about [20] mg of torsemide roughly equal to [40] mg of oral furosemide.
Nitroglycerin infusion, already stopped, is not replaced.
Intravenous potassium replacement becomes none, since spironolactone now holds potassium up.
Sacubitril-valsartan, carvedilol, spironolactone and the SGLT2 inhibitor continue orally as started on day four.
Why torsemide. It is considered for steadier absorption. In TRANSFORM-HF, torsemide did not lower all-cause mortality compared with furosemide after discharge (Mentz et al., 2023), so the choice rests on absorption and his missed-dose history, not on a survival benefit.
Discharge monitoring. Daily weights at home, with a call for a gain above his discharge weight of more than 1 kg overnight or 2 kg over any seven days; basic metabolic panel in one week; clinic visit within seven days, where the diuretic dose and each new medicine are reviewed.
References
Felker, G. M., Lee, K. L., Bull, D. A., Redfield, M. M., Stevenson, L. W., Goldsmith, S. R., LeWinter, M. M., Deswal, A., Rouleau, J. L., Ofili, E. O., Anstrom, K. J., Hernandez, A. F., McNulty, S. E., Velazquez, E. J., Kfoury, A. G., Chen, H. H., Givertz, M. M., Semigran, M. J., Bart, B. A., ... O'Connor, C. M. (2011). Diuretic strategies in patients with acute decompensated heart failure. New England Journal of Medicine, 364(9), 797-805. https://doi.org/10.1056/NEJMoa1005419
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., Fang, J. C., Fedson, S. E., Fonarow, G. C., Hayek, S. S., Hernandez, A. F., Khazanie, P., Kittleson, M. M., Lee, C. S., Link, M. S., ... Yancy, C. W. (2022). 2022 AHA/ACC/HFSA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145(18), e895-e1032. https://doi.org/10.1161/CIR.0000000000001063
Mentz, R. J., Anstrom, K. J., Eisenstein, E. L., Sapp, S., Greene, S. J., Morgan, S., Testani, J. M., Harrington, A. H., Sachdev, V., Ketema, F., Kim, D.-Y., Desvigne-Nickens, P., Pitt, B., Velazquez, E. J., TRANSFORM-HF Investigators, Adams, K. F., Bhatt, K., DeWald, T., Axsom, K. M., ... Smart, F. (2023). Effect of torsemide vs furosemide after discharge on all-cause mortality in patients hospitalized with heart failure: The TRANSFORM-HF randomized clinical trial. JAMA, 329(3), 214-223. https://doi.org/10.1001/jama.2022.23924
Metra, M., Davison, B., Bettari, L., Sun, H., Edwards, C., Lazzarini, V., Piovanelli, B., Carubelli, V., Bugatti, S., Lombardi, C., Cotter, G., & Dei Cas, L. (2012). Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circulation: Heart Failure, 5(1), 54-62. https://doi.org/10.1161/CIRCHEARTFAILURE.111.963413
How this MN650 Unit 10 example is structured
Days organize the case because the course treats acute pharmacotherapy as a sequence in which each decision alters the next patient. Every day uses the same subheads, assessment, change, reason, monitoring, so a marker can trace any drug from its first order to its last. Two decisions receive extended argument. On day three the paper resists the reflex to stop diuresis when creatinine rises, citing Metra and colleagues (2012) on why a modest rise during effective decongestion lacks the prognosis it once seemed to carry, while naming the findings that would change its mind. The transfer section then does the arithmetic this unit's final assessment usually targets: oral furosemide bioavailability is variable and roughly half, so a direct milligram swap would underdose; torsemide is considered for steadier absorption, with TRANSFORM-HF (2023) cited for its finding of no mortality difference. A discharge monitoring line closes the paper.
Get an MN650 Unit 10 example written to your instructions
Share the whole Unit 10 case your MN650 section assigned, every day of data if it runs that long, plus the rubric and whatever template the final paper uses. Nothing is charged for a first sample, which generally arrives within 24-48h and follows each drug from first order to transfer, with every intravenous-to-oral conversion shown and sourced. The paper above is an original model document written by our desk, not a submitted student paper and not an official Purdue University Global document.
MN650 Unit 10 questions, answered
Does the final case have to cover every day of the stay?
Only as far as the prompt requires. Many final cases give a few decision points rather than a full stay, and the sample adopts the structure the prompt sets. Organizing by day works well when the case supplies daily data, because it lets a marker trace each drug; with fewer data points, the sample organizes by decision instead.
How detailed should the conversion arithmetic be?
Detailed enough to check. The sample shows the intravenous dose, the bioavailability assumption and its source, the resulting oral dose, and any rounding to an available tablet strength, each bracketed. Showing the steps matters because conversion errors are common, and a marker can only award reasoning set out where it can be followed.
Can the case use a condition other than heart failure?
Yes. Sepsis, gastrointestinal bleeding, diabetic ketoacidosis and many other admissions work in the same format, since each involves drips that become tablets and decisions that change daily. The sample follows the condition the prompt supplies, and the day-by-day structure with a converted transfer table carries over unchanged.